



Trethera and UCLA enter into research collaboration agreement for the development of novel anti-cancer agents

Beverly Hills, CA, 23 March 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced that they have entered into a collaborative research agreement with the University of California, Los Angeles (UCLA) to develop novel anti-cancer agents.

Under the formal agreement, UCLA and Trethera will undertake collaborative research activities intended to support Trethera's technology platform which is based on the pharmacologic blockade of DNA synthesis and DNA repair pathways.

Dr. Holldack, CEO of Trethera, said: "We believe that our drug development capabilities combined with the scientific expertise of UCLA's investigators in cancer biology, will produce a synergistic collaboration purposed to advance new therapeutics into clinical development."

-End-

For more information, please contact:

Trethera
Dr. Johanna Holldack, CEO

Tel: +1 310 997 278
jholldack@trethera.com

Instinctif Partners
Dr. Christelle Kerouedan

Tel: +44 (0)20 7457 2020
trethera@instinctif.com

NOTES TO EDITORS

About Trethera

Trethera is a biotechnology company focused on the discovery and development of innovative small molecules that precisely control nucleotide metabolism and DNA replication and integrity for the treatment of malignant diseases.

The Company is building a pipeline of oncology products by harnessing its proprietary technology platform which is based on regulatory checkpoints in the complex system of nucleotide metabolism.

Trethera's lead compound DI-87 (TRE-515) is advancing through pre-clinical development with programs in both Leukemia and Solid Tumors. It is an oral small molecule inhibitor of Deoxycytidine Kinase, an important enzyme implicated in cancer cell proliferation. TRE-515 is being developed as a combination therapy and it is anticipated that the first clinical trial will commence in the second half of 2017.

The Company has a strong and growing patent position and an exclusive license from UCLA for patents relating to its platform and Deoxycytidine Kinase Inhibitors.

Trethera is located in California, U.S.

For more information, please visit the website: www.trethera.com.